Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | FGB | P02675 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225688 | 0.89 | PDE10A (0.47) | LMNATHRBARL3MBTL1POLB | |
| SCHEMBL2633104 | 0.82 | PKM (0.42) | PKMNPC1PKLRRAB9ALMNA | |
| SCHEMBL20456067 | 0.81 | NISCH (0.43) | PKMNPC1PKLRRAB9ALMNA | |
| SCHEMBL26504063 | 0.81 | CD274 (0.41) | PKMNPC1PKLRRAB9ALMNA | |
| SCHEMBL10176854 | 0.78 | RORC (0.46) | PKMNPC1PKLRRAB9ALMNA | |
| SCHEMBL7767339 | 0.76 | CYP2D6 (0.46) | RAB9ALMNA | |
| SCHEMBL762353 | 0.76 | ALDH1A1 (0.45) | PKMNPC1PKLRRAB9AAR | |
| SCHEMBL519949 | 0.75 | GAA (0.46) | PKMNPC1PKLRRAB9AAR | |
| SCHEMBL30781179 | 0.75 | GAA (0.46) | PKMNPC1PKLRRAB9AAR | |
| SCHEMBL12868285 | 0.73 | KDM1A (0.43) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-09-07 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PKM 2300/4885NPC1 1727/4885PKLR 1994/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | PKM 1403/4885NPC1 2197/4885PKLR 1558/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | PKM 1403/4885NPC1 2197/4885PKLR 1558/4885 |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | PKM 4364/4885NPC1 3308/4885PKLR 3873/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | PKM 1403/4885NPC1 2197/4885PKLR 1558/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | PKM 2300/4885NPC1 1727/4885PKLR 1994/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PKM 2300/4885NPC1 1727/4885PKLR 1994/4885 |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | PKM 4364/4885NPC1 3308/4885PKLR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.